Recent Updates — ATOS

Atossa Therapeutics announced that its board approved a plan to issue one contingent value right (CVR) per share of common stock, stapled to existing shares. These CVRs entitle holders to receive 25% of the net proceeds from the monetization of Atossa’s first qualifying rare pediatric disease priority review voucher, subject to an aggregate payment cap of $50 million. The company has received FDA rare pediatric disease designations for its lead candidate (Z)-endoxifen in Duchenne muscular dystrophy and McCune-Albright syndrome, but no product is currently approved and no voucher has been awarded. Atossa notes that disclosed priority review voucher sales have ranged from $100 million to $220 million over the past 18–24 months, though this does not guarantee future value. The CVRs will expire on December 31, 2036, if no qualifying voucher is awarded. Atossa Therapeutics operates as a clinical-stage biopharmaceutical company developing innovative medicines in oncology and rare diseases.

Atossa Therapeutics reported second quarter 2026 financial results and provided a corporate update. The company raised $4.5 million in upfront gross proceeds from a registered direct offering of common stock and warrants, with potential additional proceeds up to $12 million upon full warrant exercise. Total operating expenses were $8.7 million for the three months ended June 30, 2026, compared to $9.0 million in the prior year period. The company also announced that enrollment in its Phase 2 EVANGELINE trial was completed and highlighted new preclinical data regarding (Z)-endoxifen's potential in rare pediatric diseases and breast cancer. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need.

Atossa Therapeutics, Inc. entered into a securities purchase agreement on June 10, 2026, for a registered direct offering of 1,363,638 shares of common stock and Series A and B warrants. The combined offering price is $3.30 per share, with the company expecting net proceeds of approximately $4.1 million after expenses. The warrants have an exercise price of $4.40 per share and could provide an additional $12 million in gross proceeds if fully exercised. Rodman & Renshaw LLC is serving as the exclusive placement agent. Net proceeds are intended for clinical development, working capital, and general corporate purposes. Atossa Therapeutics is a biopharmaceutical company focused on developing therapeutic products.